Effects and safety profile of betahistine in patients in the Russian contingent of OSVaLD, an open-label observational study in vestibular vertigo

We report here data from the >200 patients recruited in Russia to take part in OSVaLD, a 12-week, open-label, post-marketing surveillance study of the response to betahistine 48 mg/day in vertigo of peripheral vestibular origin carried out in a total of 13 countries. The primary efficacy endpoint...

Full description

Saved in:
Bibliographic Details
Published in:International journal of general medicine 2015-01, Vol.8 (default), p.47-53
Main Authors: Morozova, Svetlana Vyacheslavovna, Alekseeva, Natalia Stepanovna, Lilenko, Sergey Vasilyevich, Matsnev, Eduard Ivanovich, Melnikov, Oleg Anatol'evich
Format: Article
Language:English
Subjects:
Agonists (Biochemistry)
anxiety
betahistine
Clinical trials
depression
Disease
dizziness
Drug dosages
Drug therapy
Epidemiology
Management
Observational studies
Original Research
Patient outcomes
Patients
Population
Quality of life
Russia
Statistical analysis
Studies
Vertigo
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report here data from the >200 patients recruited in Russia to take part in OSVaLD, a 12-week, open-label, post-marketing surveillance study of the response to betahistine 48 mg/day in vertigo of peripheral vestibular origin carried out in a total of 13 countries. The primary efficacy endpoint was change in the Dizziness Handicap Inventory (DHI; 100-point scale). Changes in Hospital Anxiety and Depression Scale (HADS) and Medical Outcomes Study Short-Form 36, version 2 (SF-36v2(®)) scores were a priori secondary Outcomes. Total DHI score improved by 43 points during betahistine treatment. This aggregate improvement was equally distributed across the three domains of the DHI (physical, emotional, and functional; P
ISSN:1178-7074
1178-7074
DOI:10.2147/IJGM.S73842